Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 494 Results

Page 2 of 50«123 4 5...10 20 30...»Last »

March 24, 2026

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

March 4, 2026

DBV Technologies to Participate in Upcoming March Investor Conferences

March 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

February 28, 2026

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

February 10, 2026

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN^® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

February 9, 2026

DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit

February 5, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

January 16, 2026

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

January 12, 2026

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

January 7, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Page 2 of 50«123 4 5...10 20 30...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top